Zostavax Clinical Efficacy Trials For 50-59 Year-Olds Needed, Cmte. Says
Executive Summary
Merck should conduct full efficacy trials for its zoster vaccine Zostavax in adults aged 50-59, not just immunologic bridging studies, FDA's Vaccines & Related Biological Products Advisory Committee recommended at its Dec. 15 meeting
You may also be interested in...
Merck Zostavax Gets Mid-Range Price, Loses Younger Age Group
Merck's newly approved herpes zoster vaccine Zostavax is priced in the middle of the company's cost-effectiveness estimates
Merck Zostavax Gets Mid-Range Price, Loses Younger Age Group
Merck's newly approved herpes zoster vaccine Zostavax is priced in the middle of the company's cost-effectiveness estimates
Merck RotaTeq Observational Study For Intussusception Will Enroll 28,000
A post-marketing observational study for Merck's RotaTeq will enroll 28,000 patients to track reports of intussusception and other potential adverse events, the company told FDA's Vaccines & Related Biological Products Advisory Committee at its Dec. 14 meeting